Federal Register / Vol. 69, No. 219 / Monday, November 15, 2004 / Notices 65609

the methodology and assumptions used; 

(3) ways to enhance the quality, utility, 

and clarity of the information to be 

collected; and (4) ways to minimize the 

burden of the collection of information 

on those who are to respond, including 

the use of appropriate automated, 

electronic, mechanical, or other 

technological collection techniques or 

other forms of information technology.

FOR FURTHER INFORMATION CONTACT: To 

request more information on the 

proposed project or to obtain a copy of 

the data collection plans and 

instruments, contact Dr. Linda Kupfer, 

Fogarty International Center, National 

Institutes of Health, 16 Center Drive, 

Building 16, Bethesda, MD 20892–6705 

or call non-toll-free number 301–496–

3288 or E-mail your request, including 

your address to: Kupferl@mail.nih.gov. 

Comments Due Date: Comments 

regarding this information collection are 

best assured of having their full effect if 

received within 60-days of the date of 

this publication.

Dated: November 5, 2004. 

Richard Miller, 

Executive Officer, FIC, National Institutes of 

Health.

[FR Doc. 04–25281 Filed 11–12–04; 8:45 am] 

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Government-Owned Inventions; 

Availability for Licensing

AGENCY: National Institutes of Health, 

Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: The inventions listed below 

are owned by an agency of the U.S. 

Government and are available for 

licensing in the U.S. in accordance with 

35 U.S.C. 207 to achieve expeditious 

commercialization of results of 

federally-funded research and 

development. Foreign patent 

applications are filed on selected 

inventions to extend market coverage 

for companies and may also be available 

for licensing.

ADDRESSES: Licensing information and 

copies of the U.S. patent applications 

listed below may be obtained by writing 

to the indicated licensing contact at the 

Office of Technology Transfer, National 

Institutes of Health, 6011 Executive 

Boulevard, Suite 325, Rockville, 

Maryland 20852–3804; telephone: 301/

496–7057; fax: 301/402–0220. A signed 

Confidential Disclosure Agreement will 

be required to receive copies of the 

patent applications. 

Metal Chelators and Target-Moiety 

Complexes for Imaging 

Martin W. Brechbiel and Thomas 

Clifford (NCI). 

U.S. Provisional Application filed 23 

Aug 2004 (DHHS Reference No. E–

317–2004). 

Licensing Contact: Michael Shmilovich; 

301/435–5019; 

shmilovm@mail.nih.gov.

Available for licensing and 

commercial development are 

bifunctional metal chelators, metal 

chelator-targeting moiety complexes, 

metal chelator-targeting moiety-metal 

conjugates, kits, and methods of 

preparing them. These chelators are 

useful in diagnosing and/or treatment of 

cancer and thrombosis. The metal 

chelators may be used in conventional 

and solid-phase synthetic methods to 

form targeting moieties (e.g., peptides, 

and Starburst polyamidoamine 

dendrimers (PAMAM), capable of 

conjugating diagnostic and/or 

therapeutic metals. The formulae for 

two such chelators is shown below:

Anti-HIV Peptide Secreting Bacteria: 

Therapeutics and Methods of Use 

Dean Hamer (NCI). 

U.S. Provisional Application No. 60/

604,051 filed 25 Aug 2004 (DHHS 

Reference No. E–233–2004/0–US–01). 

Licensing Contact: Michael Shmilovich; 

301/435–5019; 

shmilovm@mail.nih.gov.

Available for licensing and 

commercial development are genetically


EN15NO04A.054</GPH>
65610 Federal Register / Vol. 69, No. 219 / Monday, November 15, 2004 / Notices 

engineered commensal bacteria 

compositions that secrete HIV 

infectivity interfering peptides with the 

aid of co-expressed translocation 

mediators such as HylB, HylD or tolC

gene products. The bacteria can be, for 

example, Escherichia coli and are 

preferably those that colonize the 

gastrointestinal or genitourinary tracts. 

The secreted anti-HIV peptide can be a 

functional inhibitory fragment from the 

C-terminus of HIV, SHIV or SIV, or an 

inhibitory peptide derived from the Nterminus receptor-binding domain of 

SIV gp41, HIV–1 gp41, or HIV–2 gp41. 

The secreted anti-HIV peptide can also 

be a peptide from the allosteric domain 

of gp120, an extracellular loop of CCR5, 

an anti-CD4 immunoglobulin, a mimetic 

of CD4, an alpha-defensin or thetadefensin, a CD38 fragment homologous 

to the V3 loop of gp120, polphemusin 

II (a CXCR4 antagonist), a RANTES 

peptide that binds to CCR5 or an HIV 

surface binding peptide such as 

cyanovirin. 

Method of Assessing Ischemia in a 

Patient 

Steven Warach, Lawrence Latour 

(NINDS). 

U.S. Provisional Application No. 60/

381,611 filed 17 Mar 2002 (DHHS 

Reference No. E–082–2002/0–US–01); 

PCT Application No. PCT/US03/

15368 filed 16 May 2003 (DHHS 

Reference No. E–082–2002/0–PCT–

02). 

Licensing Contact: Michael Shmilovich; 

301/435–5019; 

shmilovm@mail.nih.gov.

Hyperintense acute reperfusion 

marker (HARM) is well correlated with 

reperfusion and is a precursor to or 

concomitant with reperfusion injury. 

The inventors have developed a novel 

technique of assessing injuries 

associated with ischemia, stroke, or 

reperfusion injury in a patient by 

administering a contract agent to the 

patient, acquiring a fluid-attenuated 

inversion-recovery (FLAIR) image, and 

observing the presence or absence of 

HARM on the acquired image. The 

technique can also be used to determine 

the effectiveness of a therapeutic 

protocol for the treatment or prevention 

of reperfusion injury in a patient that 

has previously suffered an ischemic 

event. 

This research has been described, in 

part, in Latour et al., ‘‘Early Blood-Brain 

Barrier Disruption in Human Focal 

Brain Ischemia,’’ Ann. Neurol. 2004 

56:568–477.

Dated: November 4, 2004. 

Steven M. Ferguson, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health.

[FR Doc. 04–25278 Filed 11–12–04; 8:45 am] 

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Government-Owned Inventions; 

Availability for Licensing

AGENCY: National Institutes of Health, 

Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: The inventions listed below 

are owned by an agency of the U.S. 

Government and are available for 

licensing in the U.S. in accordance with 

35 U.S.C. 207 to achieve expeditious 

commercialization of results of 

federally-funded research and 

development. Foreign patent 

applications are filed on selected 

inventions to extend market coverage 

for companies and may also be available 

for licensing.

ADDRESSES: Licensing information and 

copies of the U.S. patent applications 

listed below may be obtained by writing 

to the indicated licensing contact at the 

Office of Technology Transfer, National 

Institutes of Health, 6011 Executive 

Boulevard, Suite 325, Rockville, 

Maryland 20852–3804; telephone: 301/

496–7057; fax: 301/402–0220. A signed 

Confidential Disclosure Agreement will 

be required to receive copies of the 

patent applications. 

Infectious Clone of Human Parvovirus 

B19 and Methods of Use 

Ning Zhi et al. (NHLBI). 

U.S. Patent Application No. 10/887,770 

filed 09 Jul 2004 (DHHS Reference 

No.E–178–2004/0–US–01 and 

corresponding Canadian patent 

application (DHHS Reference No. E–

178–2004/0–CA–02). 

Licensing Contact: Susan Ano; 301/435–

5515; anos@mail.nih.gov.

This technology described in this 

patent application relates the first 

reported infectious human parvovirus 

B19 clone, methods of cloning the 

parvovirus B19 genome as well as other 

viral genomes that have secondary DNA 

structures that are unstable in bacterial 

cells. The infectious clone and methods 

of producing the same would be useful 

in producing infectious virus, which 

can in turn be used, among other things, 

to identify and develop therapeutic 

agents for treatment and/or prevention 

of human parvovirus B19 infections. 

The infectious parvovirus B19 clone is 

also available for licensing. Additional 

information about this invention can be 

found in Virology 2004, 318(1), 142–

152. 

Immunogenic Compositions for 

Eradication of Latent HIV 

Genoveffa Franchini et al. (NCI). 

U.S. Provisional Application No. 60/

536,467 filed 13 Jan 2004 (DHHS 

Reference No. E–072–2004/0–US–01); 

U.S. Provisional Application No. 60/

536,976 filed 16 Jan 2004 (DHHS 

Reference No. E–072–2004/1–US–01). 

Licensing Contact: Susan Ano; 301/435–

5515; anos@mail.nih.gov.

HIV infects CD4+ cells and, after 

incorporation of the viral genome into 

the host genome, can either produce 

infectious virus or remain latent. HIV 

that is latent presents a challenge for 

complete removal of the virus in 

infected individuals and is becoming an 

increasingly important consideration in 

the identification of potential 

therapeutics or treatment regimens. This 

patent application describes 

immunogenic compositions based on 

inhibiting the function of p28TEV

protein, the first protein expressed 

during HIV infection, for treatment of 

latent HIV infection. Specifically, these 

compositions include the p28TEV

polypeptide, a polypeptide with 

significant sequence homology to 

p28TEV, or immunogenic fragments of 

these polypeptides. Additional 

compositions include antibodies and 

other compounds that act to inhibit 

p28TEV activity. This technology can 

also be utilized to detect latent HIV in 

biological samples. These compositions 

and methods offer a potential solution 

for complete virus eradication in 

therapeutic treatment of HIV infected 

individuals. 

Accelerated Vaccination Strategies To 

Provide Protection Against Viral 

Infections 

Gary J. Nabel et al. (NIAID). 

U.S. Provisional Application No. 60/

491,933 filed 01 Aug 2003 (DHHS 

Reference No. E–317–2003/0–US–01); 

PCT Application filed on 01 Aug 2004 

(DHHS Reference No. E–317–2003/0-

PCT–02). 

Licensing Contact: Susan Ano; 301/435–

5515; anos@mail.nih.gov.

The technology described in this 

patent application relates to 

recombinant viruses for use as vaccines. 

These viruses contain a single or 

plurality of sequences encoding 

antigens from pathogenic viruses